Article
Oncology
Benjamin M. Ellingson, John Sampson, Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, John R. Floyd, Seunggu Han, Santosh Kesari, Dina Randazzo, Michael A. Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas Butowski, Melissa Coello, Nina Merchant, Fahar Merchant
Summary: The study compared different neuro-oncology criteria in an immunotherapy trial for recurrent glioblastoma and found a strong correlation between PFS and OS using mRANO, while iRANO required confirmation of progression 3 months later, resulting in more than half of the patients being censored.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Yannick Suter, Urspeter Knecht, Waldo Valenzuela, Michelle Notter, Ekkehard Hewer, Philippe Schucht, Roland Wiest, Mauricio Reyes
Summary: This dataset provides longitudinal MRI data of Glioblastoma patients, including expert ratings and rationales for selected follow-up studies, as well as pathology information and survival time for some patients. The dataset also includes segmentations from automated tools and radiomic features, which can be used for radiomics research, development and validation of automated segmentation methods, and studies on response assessment.
Review
Biochemistry & Molecular Biology
Mariceli Baia Leao Barros, Danilo do Rosario Pinheiro, Barbara do Nascimento Borges
Summary: Glioblastoma (GBM) is a highly aggressive tumor originating from neural stem cells of the central nervous system, with mutations in mitochondrial DNA (mtDNA) leading to mitochondrial dysfunction, playing a crucial role in GBM pathogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Nguyen Thi Thanh Ho, Chinmay Satish Rahane, Subrata Pramanik, Pok-Son Kim, Arne Kutzner, Klaus Heese
Summary: This review discusses the significance of the gene pair |-SRGAP2-FAM72-| in the treatment of GBM and other cancers, as well as the potential of neural stem cells in regenerative medicine. It highlights the role of the SRGAP2-Family with sequence similarity 72 (FAM72) master gene in cell renewal and differentiation, emphasizing the importance of monitoring this gene for cancer prevention and treatment.
Article
Oncology
Xin Chen, Mary Jane Lim-Fat, Lei Qin, Angie Li, Annie Bryant, Camden P. Bay, Lu Gao, Nityanand Miskin, Zaiyi Liu, J. Bryan Iorgulescu, Xiaoyin Xu, David A. Reardon, Geoffrey S. Young
Summary: The study compared the response assessment of GBM patients on ICB using iRANO and RANO criteria, showing high concordance in assessing progressive disease within 6 months of treatment initiation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Leonardo Delello Di Filippo, Juliana Hofstatter Azambuja, Jessyca Aparecida Paes Dutra, Marcela Tavares Luiz, Jonatas Lobato Duarte, Luiza Ribeiro Nicoleti, Sara Teresinha Olalla Saad, Marlus Chorilli
Summary: Glioblastoma multiforme (GBM) is the most common primary brain cancer with aggressive development and increasing resistance to drugs like temozolomide (TMZ). Functionalized nanocarriers can serve as an efficient and safe strategy for delivering TMZ, improving its biopharmaceutical properties and potentially repurposing its use in anti-GBM therapy.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Marianna Makowska, Beata Smolarz, Hanna Romanowicz
Summary: Glioblastoma multiforme (GBM) is a common, malignant brain tumor with a poor prognosis. Traditional treatments have limited success due to the tumor's infiltrating growth and resistance. The search for new therapies is crucial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Philipp Karschnia, Antonio Dono, Jacob S. Young, Stephanie T. Juenger, Nico Teske, Levin Haeni, Tommaso Sciortino, Christine Y. Mau, Francesco Bruno, Luis Nunez, Ramin A. Morshed, Alexander F. Haddad, Michael Weller, Martin van den Bent, Juergen Beck, Shawn Hervey-Jumper, Annette M. Molinaro, Nitin Tandon, Roberta Ruda, Michael A. Vogelbaum, Lorenzo Bello, Oliver Schnell, Stefan J. Grau, Susan M. Chang, Mitchel S. Berger, Yoshua Esquenazi, Joerg-Christian Tonn
Summary: This study retrospectively analyzed 681 patients with first recurrence of IDH wild-type glioblastomas. It found that re-resection could prolong the survival time of patients, and residual contrast-enhancing tumor of 1 cm³ or less had longer survival than non-surgical management. Complete resection according to the RANO resect classification had a better prognosis. Patients without postoperative deficits who received (radio-)chemotherapy had enhanced survival associations with smaller residual contrast-enhancing tumors. However, resection of non-contrast-enhancing tumor did not prolong survival.
Article
Oncology
Jeevan Ghosalkar, Vinay Sonawane, Tejal Pisal, Swati Achrekar, Radha Pujari, Ashish Chugh, Padma Shastry, Kalpana Joshi
Summary: GBM treatment is an area of high unmet need. Repurposing existing drugs can be an attractive choice. In this study, we have identified a unique mechanism of action of pyronaridine (PYR) against GBM through upregulation of a tumor suppressor protein, Par-4, and elucidated the complex network of pathways mediated through Par-4 leading to GBM cell death.
Review
Clinical Neurology
Dan Qi, Jing Li, C. Chad Quarles, Ekokobe Fonkem, Erxi Wu
Summary: This article summarizes the current challenges in the assessment of therapy response in patients with glioblastoma. It discusses the use of quantitative imaging, liquid biomarkers, and machine intelligence for the early prediction of therapy response and tumor progression to guide clinical decision making.
Review
Pharmacology & Pharmacy
Wei Wu, Jessica L. Klockow, Michael Zhang, Famyrah Lafortune, Edwin Chang, Linchun Jin, Yang Wu, Heike E. Daldrup-Link
Summary: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with highly infiltrative nature and treatment resistance, highlighting the importance of innovative treatment strategies. The standard treatment for GBM is surgical resection followed by chemoradiotherapy, but the robust DNA repair and self-renewing capabilities of GBM cells lead to resistance against current therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Oncology
Satya Siva Kishan Yalamarty, Nina Filipczak, Xiang Li, Md Abdus Subhan, Farzana Parveen, Janaina Artem Ataide, Bharat Ashok Rajmalani, Vladimir P. Torchilin
Summary: Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to traditional cancer treatments. The unique biology of GBM cells and the blood-brain barrier contribute to this resistance. However, there are several treatment options available, including surgery, chemoradiotherapy, adjuvant chemotherapy, immunotherapy, targeted therapies, and tumor-treating fields. Ongoing clinical trials aim to improve outcomes for GBM patients.
Article
Multidisciplinary Sciences
Spyridon Bakas, Chiharu Sako, Hamed Akbari, Michel Bilello, Aristeidis Sotiras, Gaurav Shukla, Jeffrey D. Rudie, Natali Flores Santamaria, Anahita Fathi Kazerooni, Sarthak Pati, Saima Rathore, Elizabeth Mamourian, Sung Min Ha, William Parker, Jimit Doshi, Ujjwal Baid, Mark Bergman, Zev A. Binder, Ragini Verma, Robert A. Lustig, Arati S. Desai, Stephen J. Bagley, Zissimos Mourelatos, Jennifer Morrissette, Christopher D. Watt, Steven Brem, Ronald L. Wolf, Elias R. Melhem, MacLean P. Nasrallah, Suyash Mohan, Donald M. O'Rourke, Christos Davatzikos
Summary: Glioblastoma is the most common aggressive adult brain tumor. The publicly available datasets for glioblastoma studies have limitations in terms of subject number, acquisition protocol consistency, data quality, and clinical information. To address these limitations, the University of Pennsylvania has contributed the UPenn-GBM dataset, which is currently the largest publicly available collection of 630 patients diagnosed with de novo glioblastoma. This dataset includes advanced multi-parametric magnetic resonance imaging scans, clinical and molecular information, derivative volumes, expert annotations, and quantitative imaging features.
Review
Materials Science, Biomaterials
Zahra Nozhat, Shabnam Heydarzadeh, Mina Shahriari-Khalaji, Shibo Wang, M. Zubair Iqbal, Xiangdong Kong
Summary: Glioblastoma multiforme (GBM) is a difficult-to-treat brain tumor due to the blood-brain tumor barrier (BBTB) and limited available drugs. However, recent research has shown that the use of nanoscale biomaterials can overcome these challenges and improve drug delivery to the tumor site.
BIOMATERIALS SCIENCE
(2023)
Article
Oncology
Keiss Douri, Christian Iorio-Morin, Rosalie Mercure-Cyr, Gabrielle Figueiredo, Charles Jean Touchette, Laurence Masson-Cote, David Mathieu
Summary: The current RANO-BM criteria are unreliable for identifying tumor progression in patients with brain metastases treated using stereotactic radiosurgery (SRS). Using absolute diameter differences as thresholds appears to be more effective in this cohort.